Trial · NCT02556203
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Death or First Thromboembolic Event (DTE) | Rivaroxaban (Xarelto, BAY59-7939) | 68 | Participants | ||
| Number of Participants With Death or First Thromboembolic Event (DTE) | Antiplatelet | 63 | Participants | ||
| Number of Participants With Death or First Thromboembolic Event (DTE) | Rivaroxaban (Xarelto, BAY59-7939) | 105 | Participants | ||
| Number of Participants With Death or First Thromboembolic Event (DTE) | Antiplatelet | 78 | Participants | ||
| Number of Participants With Primary Bleeding Event (PBE) | Rivaroxaban (Xarelto, BAY59-7939) | 46 | Participants | ||
| Number of Participants With Primary Bleeding Event (PBE) | Antiplatelet | 31 | Participants | ||
| Number of Participants With Net-clinical Benefit | Rivaroxaban (Xarelto, BAY59-7939) | 137 | Participants | ||
| Number of Participants With Net-clinical Benefit | Antiplatelet | 100 | Participants | ||
| Number of Participants With Cardiovascular Death or Thromboembolic Event | Rivaroxaban (Xarelto, BAY59-7939) | 83 | Participants | ||
| Number of Participants With Cardiovascular Death or Thromboembolic Event | Antiplatelet | 68 | Participants | ||
| Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds | Rivaroxaban (Xarelto, BAY59-7939) | 42 | Participants | ||
| Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds | Antiplatelet | 24 | Participants | ||
| Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds | Rivaroxaban (Xarelto, BAY59-7939) | 49 | Participants | ||
| Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds | Antiplatelet | 30 | Participants | ||
| Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds | Rivaroxaban (Xarelto, BAY59-7939) | 148 | Participants | ||
| Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds | Antiplatelet | 85 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02556203/results